Reference health
Cardiotoxicity associated with targeted cancer therapies
75/75 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
6 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 75 checked references that resolve
resolves10.1677/erc.0.0080011
The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification.
resolves10.1016/S0093-7754(01)90284-2
Anticancer therapy targeting the erbB family of receptor tyrosine kinases
resolves10.1186/1471-2407-10-337
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
resolves10.1038/nrcardio.2010.121
Cardiotoxicity of anticancer treatments: what the cardiologist needs to know
resolves10.1126/science.3798106
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene
resolves10.1046/j.1464-410X.2002.02526.x
Gene amplification and overexpression of
<i>HER2</i>
in renal cell carcinoma
resolves10.1200/JCO.2009.27.3615
Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation
resolves10.1016/S0140-6736(07)61865-0
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
resolves10.1056/NEJM200103153441101
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
resolves10.1200/JCO.2005.04.9551
Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The M.D. Anderson Cancer Center Experience
resolves10.1200/JCO.2005.13.300
Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment
resolves10.1200/JCO.2008.17.9549
Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831
resolves10.1073/pnas.122249299
Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy
resolves10.1200/JCO.2005.16.584
Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas
resolves10.1200/JCO.2009.24.1661
Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
resolves10.1016/S0025-6196(11)60896-3
Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials
resolves10.1158/1078-0432.CCR-04-0225
Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2
resolves10.1200/JCO.2010.32.2701
Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?
resolves10.2165/11636760-000000000-00000
Bevacizumab as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer
resolves10.1158/1078-0432.CCR-06-1989
Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions
resolves10.1093/jnci/djm086
Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab
resolves10.1200/JCO.2005.10.017
Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer
resolves10.1200/JCO.2005.05.098
Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer
resolves10.1200/JCO.2004.11.022
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
resolves10.1053/j.seminoncol.2006.08.001
Bevacizumab in the Treatment of Metastatic Colorectal Cancer: Safety Profile and Management of Adverse Events
resolves10.1056/NEJMoa032691
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
resolves10.1200/JCO.2005.16.139
Phase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas
resolves10.1158/1078-0432.CCR-03-0627
Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias
resolves10.1001/jama.2008.656
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients
resolves10.1089/hum.1997.8.15-1737
VEGF Gene Transfer Reduces Intimal Thickening via Increased Production of Nitric Oxide in Carotid Arteries
resolves10.1182/blood-2004-01-0273
Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells
resolves10.1161/01.ATV.0000030186.66672.36
Analysis of Coagulation Cascade and Endothelial Cell Activation During Inhibition of Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Pathway in Cancer Patients
resolves10.1016/0090-6980(78)90216-2
Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species
resolves10.1161/01.HYP.0000215207.54689.31
Vascular Endothelial Growth Factor Blockade Promotes the Transition From Compensatory Cardiac Hypertrophy to Failure in Response to Pressure Overload
resolves10.1016/j.pcad.2010.06.006
Why do Kinase Inhibitors Cause Cardiotoxicity and What can be Done About It?
resolves10.1161/CIRCRESAHA.109.206920
Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics
resolves10.1111/j.1752-8062.2008.00090.x
Sunitinib‐Induced Cardiotoxicity Is Mediated by Off‐Target Inhibition of AMP‐Activated Protein Kinase
resolves10.1056/NEJMoa055229
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
resolves10.1128/MCB.24.23.10289-10299.2004
Bcr-Abl-Mediated Protection from Apoptosis Downstream of Mitochondrial Cytochrome <i>c</i> Release
resolves10.1182/blood-2004-08-3097
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
resolves10.1182/blood-2007-01-070144
Congestive heart failure is a rare event in patients receiving imatinib therapy
resolves10.1038/nm0107-13a
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
resolves10.1038/nm0107-15a
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
resolves10.1038/nm0107-13b
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
resolves10.1038/nm0107-14
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
resolves10.1158/0008-5472.CAN-07-0345
Rational Drug Redesign to Overcome Drug Resistance in Cancer Therapy: Imatinib Moving Target
resolves10.1172/JCI34252
Structural reengineering of imatinib to decrease cardiac risk in cancer therapy
resolves10.4161/cbt.10.7.12904
SU11248, A selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells
resolves10.1158/0008-5472.CAN-08-4323
Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells
resolves10.1093/annonc/mdn168
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
resolves10.1016/S0140-6736(06)69446-4
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
resolves10.1161/hc0502.103672
Platelet-Derived Growth Factor-AB Limits the Extent of Myocardial Infarction in a Rat Model
resolves10.1172/JCI39434
Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stress
resolves10.1093/jnci/djr128
Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
resolves10.1016/j.jacc.2014.07.944
2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery
The 6 references without a DOI — listed, not checked
no DOI — not checkedDifferent anthracycline derivates for reducing cardiotoxicity in cancer patients
no DOI — not checkedAnthracycline cardiomyopathy monitored by morphologic changes
no DOI — not checkedHER2-directed therapy for metastatic breast cancer
no DOI — not checkedHypertension secondary to anti-angiogenic therapy: Experience with bevacizumab
no DOI — not checkedApproval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia
no DOI — not checkedkey20180107145756_b71-mco-0-0-800
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.3892/mco.2016.800"><img src="https://citestamp.com/citestamped/10.3892/mco.2016.800/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.3892/mco.2016.800)